학술논문

A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries
Document Type
article
Source
Vox Sanguinis. 107(4)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Clinical Sciences
Prevention
Digestive Diseases
Infectious Diseases
Liver Disease
Clinical Research
HIV/AIDS
Emerging Infectious Diseases
Hepatitis
Hepatitis - C
Infection
Good Health and Well Being
Africa
Antibodies
Viral
Antigens
Viral
Blood Safety
Blood Transfusion
Donor Selection
HIV Infections
Hepatitis B
Hepatitis B Surface Antigens
Hepatitis C
Humans
Immunoenzyme Techniques
Laboratories
Pilot Projects
Quality Assurance
Health Care
Sensitivity and Specificity
blood transfusion
hepatitis B surface antigens
hepatitis C antibodies
HIV
laboratory proficiency testing
Anglophone Africa Transfusion Research Group
Blood transfusion
Hepatitis B surface antigens
Hepatitis C antibodies
Laboratory proficiency testing
Medical Physiology
Cardiovascular System & Hematology
Clinical sciences
Language
Abstract
Background and objectivesSerologic screening for the major transfusion transmissible viruses (TTV) is critical to blood safety and has been widely implemented. However, actual performance as measured by proficiency testing has not been well studied in sub-Saharan Africa. Therefore, we conducted an external quality assessment of laboratories engaged in transfusion screening in the region.Materials and methodsBlinded test panels, each comprising 25 serum samples that were pedigreed for HIV, HBsAg, HCV and negative status, were sent to participating laboratories. The panels were tested using the laboratories' routine donor screening methods and conditions. Sensitivity and specificity were calculated, and multivariable analysis was used to compare performance against mode of testing, country and infrastructure.ResultsA total of 12 African countries and 44 laboratories participated in the study. The mean (range) sensitivities for HIV, HBsAg and HCV were 91·9% (14·3-100), 86·7% (42·9-100) and 90·1% (50-100), respectively. Mean specificities for HIV, HBsAg and HCV were 97·7%, 97% and 99·5%, respectively. After adjusting for country and infrastructure, rapid tests had significantly lower sensitivity than enzyme immunoassays for both HBsAg (P